



Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Announcement Type

New announcement

Date of this announcement

Wednesday May 07, 2025

Details of +securities that have ceased

| ASX +security code | Security description | Number of +securities that have ceased | The +securities have ceased due to | Date of cessation |
|--------------------|----------------------|--|---|-------------------|
| MYXAN | PERFORMANCE RIGHTS | 17,656 | Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied | 05/05/2025 |

Refer to next page for full details of the announcement



Part 1 - Announcement Details

1.1 Name of +Entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) provide the following information about our issued capital.

1.2 Registered Number Type

ABN

Registration Number

76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

New announcement

1.5 Date of this announcement

7/5/2025



Part 2 - Details of +equity securities or +debt securities that have ceased

| | |
|---|--|
| ASX +Security Code and Description | |
| MYXAN : PERFORMANCE RIGHTS | |
| Unquoted +equity securities that have ceased | |
| Number of securities that have ceased | |
| 17,656 | |
| Reason for cessation | |
| Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied | |
| Date of cessation | Is the entity paying any consideration for the cessation? |
| 5/5/2025 | No |
| Any other information the entity wishes to notify to ASX about the cessation? | |
| <div>17,656 performance rights lapsed in accordance with Mayne Pharma's Employee Performance Rights and Option Plan</div> | |

Part 3 - Issued capital following changes

Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| MYX : ORDINARY FULLY PAID | 81,245,827 |

3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| MYXAA : CONVERTIBLE NOTES | 27,950 |
| MYXAN : PERFORMANCE RIGHTS | 5,904,603 |
| MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 695,322 |

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.